DURECT to Present at the Stifel Nicolaus Healthcare Conference

News provided by

Nov 05, 2015, 04:30 ET

CUPERTINO, Calif., Nov. 5, 2015 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Jim Brown, President and Chief Executive Officer, will be presenting at the Stifel Nicolaus Healthcare Conference on Wednesday, November 18 at 9:30 am Eastern Time. The conference is being held at the New York Palace Hotel in New York. Management will also be available for one-on-one meetings at this conference; interested institutional investors should request a one-on-one meeting through the conference coordinators.

A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2015/77203639603.cfm

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a biopharmaceutical company focused on two areas of active drug development: new therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its Epigenomic Regulator Program. Its drug development expertise is being applied primarily to the fields of pain management, CNS disorders, acute organ injury and metabolic diseases such as NAFLD/NASH. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. Late stage development programs of this nature include POSIMIR^™ (SABER^®-Bupivacaine) and REMOXY^® (ORADUR^®-oxycodone). DURECT's Epigenomic Regulator Program includes the lead molecule DUR-928 in Phase 1 development. DUR-928 is an endogenous small molecule that modulates lipid homeostasis, inflammation and cell survival. For more information, please visit www.durect.com.

NOTE: POSIMIR^™ is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. POSIDUR, REMOXY and DUR-928 are investigational drugs under development and have not been approved for sale by the U.S. Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation